# DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

> **NCT00789477** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 221 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **PROCEDURE:** Laser Photocoagulation
- **DRUG:** Intravitreal Aflibercept Injection

## Key facts

- **NCT ID:** NCT00789477
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-09
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2014-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789477, "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00789477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*